Trial Profile
Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Seliciclib (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Proof of concept; Therapeutic Use
- 10 Oct 2022 Results assessing efficacy of seliciclib for the treatment of patients with Cushing's disease in two studies ( NCT02160730 and NCT03774446) published in the Journal of Clinical Endocrinology and Metabolism.
- 06 Nov 2018 Status changed from recruiting to discontinued.
- 24 Sep 2018 According to a Food and Drug Administration media release, USFDA awarded the trial with research grant.